NEWCASTLE UNDER LYME, ENGLAND, April 21 / – Traxxec Ltd, the U.K. subsidiary of Columbia River Resources Inc. , today reports negotiations to supply Glaxo SmithKline and Catalent through its new clinical trials sales division.
As reported last week, the company has negotiated a policy with Rexam plc that allows it to sell directly in to the pharmaceutical clinical trial arena and to pharmaceutical contract and clinical research organisations.
Catalent and Glaxo SmithKline represent two of the biggest names in the contract and pharma arena, ideal customers for the new division. In addition, Traxxec is in talks with a French-based global leader in the beauty Industry. All three companies are interested in evaluating the effectiveness of RFID in their supply chain.
Such early positive results underline the importance of the new sales channels in addition to the 15-year licensing agreement currently in place with Rexam.
In a short period of time Traxxec has opened and delivered two operational sales channels, and continues to expand its market penetration. The new beauty client represents a potential new market sector which Traxxec is keen to exploit.
CEO Amy Scopes comments, “The board is pleased that the company is now delivering revenue through two sales channels and looks forward to announcing completion of the final stage of the company development, along with positive sales stories. We believe that the company, along with key partner Rexam, is ideally placed to commercially deliver on the market potential of RFID packaging solutions.”
For more information, visit http://www.Traxxec.com.
NOTES:
1. Traxxec’s technology has worldwide patent protection
2. As part of the proposed business model and product development
process the founders of Traxxec, funded by the pharmaceutical
industry, have undertaken through two pilot installations a
feasibility study on product design and as a consequence of this
work, supplied a fully commercial product for evaluation purposes to
a client with an annual buying capacity of 20,000,000 bottles.
Traxxec Ltd was incorporated specifically to exploit this IP
commercially. Since its incorporation, Traxxec Ltd has also supplied
commercial product for a live, current Phase III study in the U.S. As
part of the technology transfer to Rexam Pharma, commercial product
was successfully manufactured by the company and supported by systems
software provided by Traxxec Ltd. To date 21,000 units have been
delivered.
3. The result of the comprehensive testing led to the decision by Rexam
to enter into licensing negotiation and complete the 15-year royalty
licence agreement. The market sector for pharmaceutical product is in
excess of US$20 billion, and bottles represent 30 percent of the
available market per annum.
4. Traxxec has commercial arrangements with Assa Abloy Identification
Technologies, a Swiss-based global leader in the supply of packaged
RFID component parts and with Telsonic Ultrasonics for current and
further product development work.
5. With the global patent and the relationship with Rexam, its first
licence contract, the company is ideally positioned to deliver this
potential within this very lucrative market, with revenues from both
product sales and system integrations as well as revenues form any
further development products in line with its business model.
For further information on Traxxec’s developments within the RFID/packaging industry, visit http://www.traxxec.com.
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. The words “estimate,” “project,” “intends,” “expects,” “believes,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, well as assumptions made by, and information currently available to, management pursuant to the “safe-harbour” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made and the Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.
Source: Traxxec Ltd.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.
